An ‘intriguing’ option for hereditary haemorrhagic telangiectasia

The results of a phase II study suggest a role for thalidomide in patients with hereditary haemorrhagic telangiectasia. Published in The Lancet Haematology the study involved 31 patients with hereditary haemorrhagic telangiectasia and severe recurrent epistaxis. Each patient received thalidomide at a starting daily dose of 50 mg, which was progressively increased up to 200 ...

Already a member?

Login to keep reading.

© 2021 the limbic